On March 28, 2025, the United States Court of Appeals for the Federal Circuit issued an opinion affirming the United States District Court for the District of New Jersey decision that Mylan Laboratories Ltd. (“Mylan”) induced healthcare providers to infringe the asserted claims of U.S. Patent No. 10,143,693 (“the ’693 patent”), and that Mylan did not demonstrate by clear and convincing evidence that the ’693 patent is invalid. Janssen Pharms., Inc. v. Mylan Lab’ys Ltd., No. 2023-2042, slip op. (Fed. Cir. Mar. 28, 2025).

On February 12, 2025, the United States District Court for the District of Delaware denied defendant Parse Biosciences’s (“Parse”) motions for summary judgment that:  (i) Parse had never actually conducted any direct or indirect infringing activity with respect to the claims of certain asserted patents (the “Giresi Patent” family) or that any such infringement was de minimis and (ii) the claims of certain asserted patents (the “Brenner Patent” family) are invalid for lack of written description support and for failure to claim what the inventor “regarded as” their invention.